Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 3.79% is 51% below its 5-year average of 7.74%, near the low end of its 5-year range (2.35%–10.91%).
As of the fiscal period ended Wednesday, December 31, 2025. 10.40% below its 12-month average of 4.23%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
3.79%
RETURN ON EQUITY (ROE) AVG TTM
4.23%
RETURN ON EQUITY (ROE) AVG 3Y
6.35%
RETURN ON EQUITY (ROE) AVG 5Y
7.74%
RETURN ON EQUITY (ROE) AVG 10Y
9.26%
RETURN ON EQUITY (ROE) AVG 15Y
10.95%
RETURN ON EQUITY (ROE) AVG 20Y
10.68%
CURRENT VS TTM AVG
-10.40%
CURRENT VS 3Y AVG
-40.31%
CURRENT VS 5Y AVG
-51.00%
CURRENT VS 10Y AVG
-59.08%
CURRENT VS 15Y AVG
-65.39%
CURRENT VS 20Y AVG
-64.52%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-65.20%
vs the sector median at left
CVS Health Corp.
Market Cap
$133.25B
Return on Equity (ROE)
3.79%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$133.37B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
Market Cap
$131.47B
Return on Equity (ROE)
21.95%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$137.13B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$124.86B
Return on Equity (ROE)
7.78%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$124.82B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$142.54B
Return on Equity (ROE)
8.31%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$121.09B
Return on Equity (ROE)
22.41%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$109.30B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CVS Health Corp. (CVS) | $133.25B | 3.79% | 4.23% | 6.35% | 7.74% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.37B | 41.59% | -8.30% | 7.76% | 4.45% |
| AstraZeneca PLC (AZN)vs › | $131.47B | 21.95% | 19.16% | 15.60% | 13.86% |
| Danaher Corporation (DHR)vs › | $137.13B | 7.61% | 7.38% | 9.51% | 10.24% |
| Stryker Corporation (SYK)vs › | $124.86B | 7.78% | 14.50% | 15.05% | 14.30% |
| Intuitive Surgical, Inc. (ISRG)vs › | $124.82B | 17.28% | 15.07% | 13.91% | 13.46% |
| Pfizer Inc. (PFE)vs › | $142.54B | 8.31% | 9.04% | 13.32% | 16.07% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.09B | 22.41% | 8.96% | 15.60% | 19.47% |
| Medtronic plc (MDT)vs › | $109.30B | 9.70% | 9.71% | 8.51% | 8.44% |
| Gilead Sciences, Inc. (GILD)vs › | $161.66B | 39.19% | 19.98% | 21.60% | 19.44% |
ROE
3.8%
ROA
1.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 2.35% |
| 2024-12-31 | 6.11% |
| 2023-12-31 | 10.91% |
| 2022-12-31 | 6.03% |
| 2021-12-31 | 10.66% |
| 2020-12-31 | 10.35% |
| 2019-12-31 | 10.39% |
| 2018-12-31 | -1.02% |
| 2017-12-31 | 17.57% |
| 2016-12-31 | 14.44% |
| 2015-12-31 | 14.08% |
| 2014-12-31 | 12.23% |
| 2013-12-31 | 12.10% |
| 2012-12-31 | 10.26% |
| 2011-12-31 | 9.10% |
| 2010-12-31 | 9.09% |
| 2009-12-31 | 10.33% |
| 2008-12-31 | 9.29% |
| 2007-12-31 | 8.42% |
| 2006-12-31 | 13.80% |
| 2005-12-31 | 14.70% |
| 2004-12-31 | 13.15% |
| 2003-12-31 | 14.07% |
| 2002-12-31 | 13.79% |
| 2001-12-31 | 9.05% |
| 2000-12-31 | 17.33% |
| 1999-12-31 | 17.26% |
| 1998-12-31 | 12.36% |
| 1997-12-31 | 3.40% |
| 1996-12-31 | 9.48% |
